Grass pollen-derived allergy immunotherapeutic - ASIT Biotech

Drug Profile

Grass pollen-derived allergy immunotherapeutic - ASIT Biotech

Alternative Names: gp-ASIT+™; gpASIT+

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioTech Tools
  • Class Allergens; Allergy immunotherapies; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 14 Sep 2017 ASIT biotech anticipates FDA feedback on clinical development of grass pollen-derived allergy immunotherapeutic in the fourth quarter of 2017
  • 14 Sep 2017 ASIT biotech plans the phase III ABT-011 trial for Allergic rhinoconjunctivitis in Germany in the second half of 2018
  • 03 Jul 2017 Efficacy data from a phase III trial Allergic rhinoconjunctivitis released by ASIT biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top